Jun 18, 2020
Almirall Announces FDA Approval Of Updated Label For Seysara® (Sarecycline) Tablets
May 29, 2020
Menlo Therapeutics Receives FDA Approval of ZILXI(TM) (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
Feb 18, 2020
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
Feb 06, 2020
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
Jan 14, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Jan 09, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
Nov 04, 2019
Foamix Announces Publication of AMZEEQ(TM) (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
Oct 18, 2019
Foamix Receives FDA Approval of AMZEEQ(TM) Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
Jun 19, 2019
Global Acne Market Spotlight 2017-2018 & 2019-2026 - ResearchAndMarkets.com
May 22, 2019
BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea
Mar 04, 2019
BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea
Jan 17, 2019
Novel Oral Antibiotic Treatment Seysara(TM) (sarecycline) Now Available
Nov 26, 2018
Antibiotics: Global Markets to 2023
Jul 31, 2018
BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea
Mar 20, 2018
U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions
Feb 01, 2018
Neogen releases easiest dairy antibiotic tests
Jan 12, 2018
BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month
Dec 20, 2017
FDA Accepts New Drug Application For Seysara(TM) (Sarecycline) For The Treatment Of Moderate To Severe Acne
Dec 13, 2017
Hovione Announces Enrollment of First Patient in MARS, a Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Dec 12, 2017
Novasep Signs Manufacturing Agreement with Clinical-stage Biopharmaceutical Company Tetraphase for Eravacycline API